Cancer

Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference

BASKING RIDGE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…

11 months ago

Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

FLORHAM PARK, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused…

11 months ago

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology…

11 months ago

Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels

Rapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE…

11 months ago

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company…

11 months ago

Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the…

11 months ago

PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

FDA-cleared amended trial design; First site initiation expected Q1 2025PRINCETON, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation…

11 months ago

Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no…

11 months ago

Collegium Appoints Nancy S. Lurker to its Board of Directors

STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Nancy S.…

11 months ago

Celebrating the Winners of the Inaugural Sony Women in Technology Award with Nature

NEW YORK and LONDON and BERLIN and TOKYO, Feb. 4, 2025 /PRNewswire/ -- Sony Group Corporation (Sony) and Nature are proud…

11 months ago